Inhibition of Intimal Thickening in the Rat Carotid Artery Injury Model by a Nontoxic Ras Inhibitor

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 2, 2004, Pages 363-368

  George, Jacob ^a,c   Sack, Jessica ^a   Barshack, Iris ^b   Keren, Pnina ^a   Goldberg, Iris ^b   Haklai, Roni ^a   Elad Sfadia, Galit ^a   Kloog, Yoel ^a   Keren, Gad ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Intimal thickening; Proliferation; Ras; Smooth muscle cell

Indexed keywords

FARNESYLTHIOSALICYLIC ACID; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE SYNTHASE; RAS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOSCLEROSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON DILATATION; CAROTID ARTERY INJURY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATION; INTIMA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RAT; SMOOTH MUSCLE FIBER; SPLEEN CELL; VASCULAR SMOOTH MUSCLE;

ANIMALS; CAROTID ARTERY INJURIES; CAROTID ARTERY, COMMON; CELL DIVISION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; FARNESOL; GTP-BINDING PROTEINS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH, VASCULAR; RAS PROTEINS; RATS; RATS, WISTAR; SALICYLIC ACIDS; SPLEEN; TUNICA INTIMA;

EID: 1042302752     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000112021.98971.f0     Document Type: Article

References (27)

1. Popma JJ, Califf RM, Topol EJ. Clinical trials of restenosis after coronary angioplasty. Circulation. 1991;84:1426-1436.
2. Libby P, Schwartz D, Brogi B, Tanaka H, Clinton SK. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation. 1992;86:11147-11152.
3. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
4. Marx SO, Marks AR. The development of rapamycin and its application to stent restenosis. Circulation. 2001;104:852-855.
5. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Ann Rev Biochem. 1999;68:913-963.
6. Rebollo A, Martinez CA. Ras proteins: recent advances and new functions. Blood. 1999;94:2971-2980.
7. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene. 1998;17: 1395-1413.
8. Reuther GW, Der CJ. The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr Opin Cell Biol. 2000;12: 157-165.
9. Bar-Sagi D, Hall A. Ras and Rho GTPases: a family reunion. Cell. 2000;103:227-238.
10. Marciano D, Ben-Bar G, Marom M, Egozi Y, Haklai R, Kloog Y. Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras dependent cell growth. J Med Chem. 1995;38:1267-1272.
11. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11-22.
12. Prendergast GC. Actin' up: RhoB in cancer and apoptosis. Nat Rev Cancer. 2001;1:162-168.
13. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR, Pai JK. K-and N-ras geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem. 1997; 272:14459-14464.
14. Indolfi C, Avvedimento EV, Rapacciuolo A, Di Lorenzo E, Esposito G, Stabile E, Feliciello A, Mele E, Giuliano P, Condorelli G. Inhibition of cellular ras prevents smooth muscle proliferation after vascular injury in vivo. Nat Med. 1995;1:541-545.
15. Ueno H, Yamamoto H, Ito S, Li JJ, Tekeshita A. Adenovirus-mediated transfer of a dominant-negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo. Arterioscler Thromb Vasc Biol. 1997; 17:898-904.
16. Kloog Y, Cox AD, Sinensky M. Concepts in Ras-directed therapy. Exp Opin Invest Drugs. 1999;8:2121-2140.
17. Marom M, Haklai R, Ben-Baruch G, Marciano D, Egozi Y, Kloog Y. Selective inhibition of ras-dependent cell growth by farnesyl thiosalicylic acid. J Biol Chem. 1995;270:22263-22270.
18. George J, Afek A, Keren P, Herz I, Goldberg I, Haklai R, Kloog Y, Keren G. Functional inhibition of Ras by S-trans, trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice. Circulation. 2002;21:2416-2422.
19. Reif S, Weisz B, Aeed H, Gana-Weis M, Zaidel L, Avni Y, Romanelli RG, Pinzani M, Kloog Y, Bruck R. The Ras antagonist, Farnesyl thiosalicylic acid (FTS) inhibits experimentally induced liver Cirrhosis in rats. J Hepatol. 1999;31:1053-1061.
20. Smith JB, Brock TA. Analysis of angiotensin-stimulated sodium transport in cultured smooth muscle cells from rat aorta. J Cell Physiol. 1983;114: 284-290.
21. George J, Greenberg S, Barshack I, Singh M, Pri-Chen S, Laniado S, Keren G. Immunization against heat shock protein 70 accelerates neointimal thickening in the rat carotid injury model. J Am Coll Cardiol. 2001;38:1564-1569.
22. Haklai R, Weisz MG, Elad G, Paz A, Marciano D, Egozi Y, Ben-Baruch G, Kloog Y. Dislodgement and accelerated degradation of Ras. Biochemistry. 1998;37:1306-1314.
23. Jansen B, Schlagbauer-Wadl H, Kahr H, Ress E, Mayer B, Eichler H, Gana-Weisz M, Ben-David E, Kloog Y, Wolff K. Novel ras antagonist blocks human melanoma growth. Proc Natl Acad Sci USA. 1999;96: 14019-14024.
24. Halaschek-Wiener J, Kloog Y, Wacheck V, Jansen B. Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo. J Invest Dermatol 2003;120:109-115.
25. Zohlnhofer D, Richter T, Neumann FJ, Nuhrenberg T, Wessely R, Brandl R, Murr A, Klein CA, Baeuerle PA. Transcriptome analysis reveals a role of interferon-γ in human neointima formation. Mol Cell. 2001;7: 1059-1069.
26. Kouchi H, Nakamura K, Fushimi K, Sakaguchi M, Miyazaki M, Ohe T, Namba M. Manumycin A, inhibitor of ras farnesyltransferase, inhibits proliferation and migration of rat vascular smooth muscle cells. Biochem Biophys Res Commun. 1999;264:915-920.
27. Faxon DP. Systemic drug therapy for restenosis "Déjà vu all over again." Circulation. 2002;106:2296-2298.